Skip to content

The effect of premedication Hyoscine-N-butylbromide before Hysterosalpingography for diagnosis of proximal tubal obstruction in Infertile Women : A Randomized Double-Blind Controlled Trial

The effect of premedication Hyoscine-N-butylbromide before Hysterosalpingography for diagnosis of proximal tubal obstruction in Infertile Women : A Randomized Double-Blind Controlled Trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20151121001
Enrollment
144
Registered
2015-11-21
Start date
2016-06-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

results of tubal occlusion from HSG in infertile women&#44

Interventions

The experiment group receive Hyoscine 10 mg (2 tablets).,The control group receive placebo.
Experimental Drug,Placebo Comparator Drug

Sponsors

Songklanagarind hospital
Lead Sponsor
Obstertrics and Gynecology department
Collaborator

Eligibility

Sex/Gender
Female
Age
19 Years to 42 Years

Inclusion criteria

Inclusion criteria: The infertile women who indicated for investigation hysterosalpingography were enrolled.

Exclusion criteria

Exclusion criteria: 1) contraindications to Hyoscine or NSAID - known sensitivity to these drugs 2) known sensitivity to contrast media 3) abnormal uterine bleeding 4) genital tract infection 5) suspected pregnancy

Design outcomes

Primary

MeasureTime frame
To evaluate results of tubal occlusion complete HSG procedure, result To evaluate results of tubal occlusion from HSG in infertile women, compare between Hyoscine group a

Secondary

MeasureTime frame
Pain score during procedure and post post procedure Visual anolog scale ,the adverse effects of drug and procedure after procedure such as dizziness, syncope, tachycardia, nausea, vomiting, pelvic pain, bleeding

Countries

Thailand

Contacts

Public ContactAkarawit Jitchanwichai

Medicine Songklanagarind University

Akarawit.j@gmail.com0865796409

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026